Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey.

ABSTRACT:

Purpose

Identify factors influencing audiological care for chemotherapy-induced ototoxicity from the perspectives of oncology providers in the Veterans Health Administration (VA), and quantify audiology service use among Veterans receiving ototoxic chemotherapies.

Methods

We surveyed VA oncology providers to identify barriers and facilitators to ototoxicity management (OtoM). We also conducted a VA-wide retrospective cohort analysis over a 5-year period to quantify audiology service use among Veterans who received cisplatin, carboplatin, or oxaliplatin chemotherapy.

Results

A total of 30,643 Veterans received platinum-based chemotherapy from 2014 to 2019. Few of them (< 10% on cisplatin, < 5% on carboplatin or oxaliplatin) accessed audiology services within a year of

SUBMITTER: Lacey C 

PROVIDER: S-EPMC12906773 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature